From Trials to the Clinic: Using a Therapy With a Novel MOA to Treat Patients With DME
One of the challenges associated with current anti-VEGF therapies for the management of DME is the need for frequent injections and the potential impact on adherence and vision outcomes. Join Dr. John Kitchens and Dr. Maria Berrocal as they share their experiences treating their DME patients using a therapy with a novel mechanism of action, and how those patient outcomes have influenced their extension decisions and treatment management approaches. This special episode of New Retina Radio, and its content, is supported by Genentech USA, Inc.